Continuous Glucose Monitoring for Postkidney Transplantation in Patients With Pre-existing Type 2 Diabetes

Area of Science:

• Endocrinology
• Nephrology
• Transplantation

Background:

• Kidney transplantation presents unique glycemic control challenges for patients with type 2 diabetes (T2DM).
• Immunosuppressive therapy and metabolic shifts post-transplant complicate diabetes management.
• Prednisone taper is a critical period requiring careful glucose monitoring.

Purpose of the Study:

• To evaluate the effectiveness of a continuous glucose monitor (CGM)-based insulin titration protocol.
• To assess glycemic control (glucometrics) during prednisone taper in kidney transplant recipients with T2DM.
• To determine if CGM guidance can optimize insulin dosing in this specific patient population.

Main Methods:

• Pilot study involving kidney transplant recipients with pre-existing T2DM on insulin therapy.
• Utilized CGM metrics to guide insulin dose adjustments over a 3-month period, with data analyzed up to 6 months.
• Monitored CGM metrics, insulin and prednisone doses, kidney function, and clinical outcomes.

Main Results:

• Significant increase in Time in Range (TIR): 44.2% to 60.8% at 3 months (p=0.005) and 72.9% at 6 months (p<0.001).
• Average glucose levels decreased from 194.7 mg/dL to 148.0 mg/dL by 6 months (p<0.001).
• No significant increase in hypoglycemia (TBR <54 mg/dL), with a slight increase in the 54-69 mg/dL range.

Conclusions:

• CGM-based insulin titration protocol effectively improves glycemic control in kidney transplant recipients with T2DM.
• The protocol demonstrates potential for optimizing insulin dosing during prednisone taper.
• Findings offer valuable insights for managing similar patient demographics and treatment regimens.